Stool DNA testing is intended to screen healthy people with no symptoms for colon cancer or precancerous polyps. The test also measures blood in the stool. Research shows the stool DNA test is effective at detecting colon cancer and precancerous polyps.
How stool DNA testing works
The stool DNA test detects signature DNA changes in tumor cells that are found in the stool.
Because the lining of the colon is always shedding cells, including cells from the surface of polyps and cancers, these markers are available in the stool. A stool DNA test can identify several of these markers, indicating the presence of precancerous polyps or colon cancer.
Many different DNA changes may be present in colon cancer cells, so the stool DNA test looks for a panel of DNA markers. Also, because DNA markers may be present in only tiny amounts in stool, very sensitive laboratory methods are required.
Aug. 13, 2014
- Imperiale TF, et al. Multitarget stool DNA testing for colorectal cancer screening. The New England Journal of Medicine. 2014;370:1287.
- Ahlquist DA, et al. Next generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology. 2012;142:248.
- Heigh RI, et al. Detection of colorectal serrated polyps by stool DNA testing: Comparison with fecal immunochemical testing for occult blood (FIT). PLOS One. 2014;9:e85659. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0085659. Accessed March 18, 2014.
- Ahlquist DA, et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clinical Gastroenterology and Hepatology. 2012;10:272.
- Fecal DNA testing in screening for colorectal cancer in average-risk adults. Rockville, Md.: Agency for Healthcare Research and Quality. http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=988. Accessed March 18, 2014.
- Fletcher RH. Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy. http://www.uptodate.com/home. Accessed March 18, 2014.
- Berger BM, et al. Stool DNA screening for colorectal neoplasia: Biological and technical bases for high detection rates. Pathology. 2012;44:80.
- Ahlquist DA, et al. Aberrantly methylated gene marker levels in stool: Effects of demographic, exposure, body mass, and other patient characteristics. Journal of Molecular Biomarkers & Diagnosis. 2012;3:e1. http://omicsonline.org/aberrantly-methylated-gene-marker-levels-in-stool-effects-of-demographic-exposure-body-mass-and-other-patient-characteristics-2155-9929.1000133.php?aid=8381. Accessed June 9, 2014.
- Lidgard GP, et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clinical Gastroenterology and Hepatology. 2013;11:1313.
- Transcript: March 27, 2014. FDA Molecular and Clinical Genetics Panel. U.S. Food and Drug Administration. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/MolecularandClinicalGeneticsPanel/ucm390219.htm. Accessed June 9, 2014.
- FDA approves first non-invasive DNA screening test for colorectal cancer. U.S. Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm409021.htm. Accessed Aug. 11, 2014.